|
1
|
Yang JD and Roberts LR: Hepatocellular
carcinoma: A global view. Nat Rev Gastroenterol Hepatol. 7:448–458.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Altekruse SF, McGlynn KA and Reichman ME:
Hepatocellular carcinoma incidence, mortality, and survival trends
in the United States from 1975 to 2005. J Clin Oncol. 27:1485–1491.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Verslype C, Rosmorduc O and Rougier P;
ESMO Guidelines Working Group: Hepatocellular carcinoma: ESMO-ESDO
clinical practice guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 23(Suppl 7): vii41–vii48. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yuan SX, Yang F, Yang Y, Tao QF, Zhang J,
Huang G, Yang Y, Wang RY, Yang S, Huo XS, et al: Long noncoding RNA
associated with microvascular invasion in hepatocellular carcinoma
promotes angiogenesis and serves as a predictor for hepatocellular
carcinoma patients' poor recurrence-free survival after
hepatectomy. Hepatology. 56:2231–2241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li C, Wu X, Zhang H, Yang G, Hao M, Sheng
S, Sun Y, Long J, Hu C, Sun X, et al: A Huaier polysaccharide
restrains hepatocellular carcinoma growth and metastasis by
suppression angiogenesis. Int J Biol Macromol. 75:115–120. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cuevas I, Layman H, Coussens L and
Boudreau N: Sustained endothelial expression of HoxA5 in vivo
impairs pathological angiogenesis and tumor progression. PLoS One.
10:e01217202015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Welti J, Loges S, Dimmeler S and Carmeliet
P: Recent molecular discoveries in angiogenesis and antiangiogenic
therapies in cancer. J Clin Invest. 123:3190–3200. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB,
Lee CN and Hsieh CY: Interleukin-6 promotes cervical tumor growth
by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene.
22:1517–1527. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Van der Veldt AA, Lubberink M, Bahce I,
Walraven M, de Boer MP, Greuter HN, Hendrikse NH, Eriksson J,
Windhorst AD, Postmus PE, et al: Rapid decrease in delivery of
chemotherapy to tumors after anti-VEGF therapy: Implications for
scheduling of anti-angiogenic drugs. Cancer Cell. 21:82–91. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ge G, Wang A, Yang J, Chen Y, Yang J, Li Y
and Xue Y: Interleukin-37 suppresses tumor growth through
inhibition of angiogenesis in non-small cell lung cancer. J Exp
Clin Cancer Res. 35:132016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar
|
|
12
|
Plummer PN, Freeman R, Taft RJ, Vider J,
Sax M, Umer BA, Gao D, Johns C, Mattick JS, Wilton SD, et al:
MicroRNAs regulate tumor angiogenesis modulated by endothelial
progenitor cells. Cancer Res. 73:341–352. 2013. View Article : Google Scholar
|
|
13
|
Zaravinos A, Radojicic J, Lambrou GI,
Volanis D, Delakas D, Stathopoulos EN and Spandidos DA: Expression
of miRNAs involved in angiogenesis, tumor cell proliferation, tumor
suppressor inhibition, epithelial-mesenchymal transition and
activation of metastasis in bladder cancer. J Urol. 188:615–623.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bo W, Hu Y, Feng X, Zhang H, Tian L and
Liu A: The tumor suppressor role of miR-4782-3p in hepatocellular
carcinoma. Oncol Rep. 35:2107–2112. 2016.PubMed/NCBI
|
|
15
|
Wang W, Zhang E and Lin C: MicroRNAs in
tumor angiogenesis. Life Sci. 136:28–35. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu X, Zhang X, Xiang J, Lv Y and Shi J:
miR-451: Potential role as tumor suppressor of human hepatoma cell
growth and invasion. Int J Oncol. 45:739–745. 2014.PubMed/NCBI
|
|
17
|
Su Z, Zhao J, Rong Z, Geng W and Wang Z:
MiR-451, a potential prognostic biomarker and tumor suppressor for
gastric cancer. Int J Clin Exp Pathol. 8:9154–9160. 2015.PubMed/NCBI
|
|
18
|
Liu D, Liu C, Wang X, Ingvarsson S and
Chen H: MicroRNA-451 suppresses tumor cell growth by
down-regulating IL6R gene expression. Cancer Epidemiol. 38:85–92.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zou Y, Guo CG and Zhang MM: Inhibition of
human hepatocellular carcinoma tumor angiogenesis by siRNA
silencing of VEGF via hepatic artery perfusion. Eur Rev Med
Pharmacol Sci. 19:4751–4761. 2015.
|
|
20
|
Shinriki S, Jono H, Ota K, Ueda M, Kudo M,
Ota T, Oike Y, Endo M, Ibusuki M, Hiraki A, et al: Humanized
anti-interleukin-6 receptor antibody suppresses tumor angiogenesis
and in vivo growth of human oral squamous cell carcinoma. Clin
Cancer Res. 15:5426–5434. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim BM, Lee DH, Choi HJ, Lee KH, Kang SJ,
Joe YA, Hong YK and Hong SH: The recombinant kringle domain of
urokinase plasminogen activator inhibits VEGF165-induced
angiogenesis of HUVECs by suppressing VEGFR2 dimerization and
subsequent signal transduction. IUBMB Life. 64:259–265. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Plate KH, Scholz A and Dumont DJ: Tumor
angiogenesis and anti-angiogenic therapy in malignant gliomas
revisited. Acta Neuropathol. 124:763–775. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Paauwe M, Heijkants RC, Oudt CH, van Pelt
GW, Cui C, Theuer CP, Hardwick JC, Sier CF and Hawinkels LJ:
Endoglin targeting inhibits tumor angiogenesis and metastatic
spread in breast cancer. Oncogene. Jan 25–2016.Epub ahead of print.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kishimoto T: Interleukin-6: From basic
science to medicine - 40 years in immunology. Annu Rev Immunol.
23:1–21. 2005. View Article : Google Scholar
|
|
25
|
Chekhonin VP, Shein SA, Korchagina AA and
Gurina OI: VEGF in tumor progression and targeted therapy. Curr
Cancer Drug Targets. 13:423–443. 2013. View Article : Google Scholar
|
|
26
|
Wang R, Zhao N, Li S, Fang JH, Chen MX,
Yang J, Jia WH, Yuan Y and Zhuang SM: MicroRNA-195 suppresses
angiogenesis and metastasis of hepatocellular carcinoma by
inhibiting the expression of VEGF, VAV2, and CDC42. Hepatology.
58:642–653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wei D, Le X, Zheng L, Wang L, Frey JA, Gao
AC, Peng Z, Huang S, Xiong HQ, Abbruzzese JL, et al: Stat3
activation regulates the expression of vascular endothelial growth
factor and human pancreatic cancer angiogenesis and metastasis.
Oncogene. 22:319–329. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Niu G, Wright KL, Huang M, Song L, Haura
E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, et al:
Constitutive Stat3 activity up-regulates VEGF expression and tumor
angiogenesis. Oncogene. 21:2000–2008. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bold G, Schnell C, Furet P, McSheehy P,
Brüggen J, Mestan J, Manley PW, Drückes P, Burglin M, Dürler U, et
al: A novel potent oral series of VEGFR2 inhibitors abrogate tumor
growth by inhibiting angiogenesis. J Med Chem. 59:132–146. 2016.
View Article : Google Scholar
|
|
30
|
Chae SS, Kamoun WS, Farrar CT, Kirkpatrick
ND, Niemeyer E, de Graaf AM, Sorensen AG, Munn LL, Jain RK and
Fukumura D: Angiopoietin-2 interferes with anti-VEGFR2-induced
vessel normalization and survival benefit in mice bearing gliomas.
Clin Cancer Res. 16:3618–3627. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ku CY, Wang YR, Lin HY, Lu SC and Lin JY:
Corosolic acid inhibits hepatocellular carcinoma cell migration by
targeting the VEGFR2/Src/FAK pathway. PLoS One. 10:e01267252015.
View Article : Google Scholar : PubMed/NCBI
|
